Nimotuzumab plus induction chemotherapy followed by radiotherapy/concurrent chemoradiotherapy plus nimotuzumab for locally advanced nasopharyngeal carcinoma: protocol of a multicentre, open-label, single-arm, prospective phase II trial

Epidermal growth factor receptor (EGFR) is a therapeutic target in nasopharyngeal carcinoma (NPC). The optimal combined modality of optimal combined modality of anti-­EGFR monoclonal antibodies, induction chemotherapy (ICT), concurrent chemotherapy and radiotherapy for NPC remains poorly defined. No...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Jing-Jing, Ding, Jian-Wu, Li, Jin-Wei, Hu, Rong-Huan, Gong, Dan, Hu, Jia-Li, Zhu, Kai-Bin, Liu, Yan, Ding, Yu-Hai, Wei, Jia-Wang, Zeng, Jian-Lun, Lu, Zhi-Bing, Yin, Wei-Hua, Ai, Su-Fen, Zha, Guo-Hua, Zhang, Zhi-Lin, Zou, Rui, Zeng, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422822/
https://www.ncbi.nlm.nih.gov/pubmed/36008072
http://dx.doi.org/10.1136/bmjopen-2021-051594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422822/
https://www.ncbi.nlm.nih.gov/pubmed/36008072
http://dx.doi.org/10.1136/bmjopen-2021-051594

Ejemplares similares